VBI VACCINES INC (VBIV) Stock Price & Overview
NASDAQ:VBIV • CA91822J2020
Current stock price
The current stock price of VBIV is 0.0653 USD. Today VBIV is down by -50.87%. In the past month the price decreased by -91.32%. In the past year, price decreased by -94.82%.
VBIV Key Statistics
- Market Cap
- 1.873M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -6.80
- Dividend Yield
- N/A
VBIV Stock Performance
VBIV Stock Chart
VBIV Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to VBIV. When comparing the yearly performance of all stocks, VBIV is a bad performer in the overall market: 99.72% of all stocks are doing better.
VBIV Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to VBIV. VBIV may be in some trouble as it scores bad on both profitability and health.
VBIV Earnings
On August 7, 2024 VBIV reported an EPS of -0.73 and a revenue of 1.21M. The company missed EPS expectations (-35.04% surprise) and missed revenue expectations (-58.27% surprise).
VBIV Forecast & Estimates
7 analysts have analysed VBIV and the average price target is 5.1 USD. This implies a price increase of 7710.11% is expected in the next year compared to the current price of 0.0653.
For the next year, analysts expect an EPS growth of 86.5% and a revenue growth -2.62% for VBIV
VBIV Groups
Sector & Classification
VBIV Financial Highlights
Over the last trailing twelve months VBIV reported a non-GAAP Earnings per Share(EPS) of -6.8. The EPS decreased by -90.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -111.34% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
VBIV Ownership
VBIV Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.76 | 360.314B | ||
| AMGN | AMGEN INC | 15.34 | 188.978B | ||
| GILD | GILEAD SCIENCES INC | 15.4 | 168.645B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.42 | 111.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.83 | 79.228B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.02 | 41.489B | ||
| INSM | INSMED INC | N/A | 30.828B | ||
| NTRA | NATERA INC | N/A | 29.443B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.978B | ||
| BIIB | BIOGEN INC | 11.6 | 26.907B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.42 | 25.134B | ||
| MRNA | MODERNA INC | N/A | 21.65B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.477B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About VBIV
Company Profile
VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The company is headquartered in Cambridge, Massachusetts and currently employs 131 full-time employees. The company went IPO on 2001-11-19. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology and a proprietary mRNA-launched eVLP (MLE) platform technology, the Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The firm is focused on targeting and overcoming significant infectious diseases, including hepatitis B (HBV), coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for coronavirus disease include VBI-2901, VBI-2905, VBI-2902, and others. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.
Company Info
IPO: 2001-11-19
VBI VACCINES INC
160 Second Street, Cambridge
Cambridge MASSACHUSETTS 02142 US
CEO: Jeffrey Baxter
Employees: 131
Phone: 16178303031
VBI VACCINES INC / VBIV FAQ
Can you describe the business of VBI VACCINES INC?
VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The company is headquartered in Cambridge, Massachusetts and currently employs 131 full-time employees. The company went IPO on 2001-11-19. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology and a proprietary mRNA-launched eVLP (MLE) platform technology, the Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The firm is focused on targeting and overcoming significant infectious diseases, including hepatitis B (HBV), coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for coronavirus disease include VBI-2901, VBI-2905, VBI-2902, and others. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.
Can you provide the latest stock price for VBI VACCINES INC?
The current stock price of VBIV is 0.0653 USD. The price decreased by -50.87% in the last trading session.
What is the dividend status of VBI VACCINES INC?
VBIV does not pay a dividend.
How is the ChartMill rating for VBI VACCINES INC?
VBIV has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
When does VBI VACCINES INC (VBIV) report earnings?
VBI VACCINES INC (VBIV) will report earnings on 2024-11-12, before the market open.
Can you provide the ownership details for VBIV stock?
You can find the ownership structure of VBI VACCINES INC (VBIV) on the Ownership tab.